Global Psychedelic therapeutics market is projected to grow at an annualized rate of ~15%, till 2030
Roots Analysis has done a detailed study on “Global Psychedelic Therapeutics Market, 2020-2030”, covering key aspects of the industry and identifying potential future growth opportunities
To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this link
Key Market Insights
- Nearly 70 players from across the world presently claim to be engaged in the development and evaluation of therapeutic candidates based on a number of psychedelic compounds, such as ketamine and psilocybin
- The pipeline features product candidates based on a variety of psychedelic drug classes, which are being investigated for a wide range of target disease indications, and having different routes of administration
- From a global perspective, this industry is anticipated to evolve significantly over the next few years as federal / regional regulators in different nations are gradually convinced of the clinical significance of this product class
- Several organizations, having realized the untapped opportunity within this emerging segment of psychedelic therapeutics, have awarded grants of over USD 275 million across 500+ instances between 2015-2020
- Several trials evaluating various psychedelic compounds against a wide range of therapeutic indication have been registered in the recent past
- The growing interest is also reflected in the partnership activity since 2017; a number of different types of deals involving various drug classes have been established across multiple geographies
- Presently, North American companies are actively consolidating their indigenous presence through strategic acquisitions; key value drivers behind such deals include both portfolio and geographical expansion
- A number of eminent scientists from renowned universities have emerged as key opinion leaders in this domain, owing to their active involvement in clinical development efforts related to interventions based on psychedelics
- Future market size, based on revenue reported from the sales of marketed and late stage psychedelic-based therapies, is anticipated to be distributed across different therapeutic areas and key geographical regions
For more information, please visit https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. History of Psychedelic Substance
3.3. Potential Therapeutic Application of Psychedelic Substance
3.4. Regulation, Toxicity Concerns, Procurement-Related Challenges and Perceptions Regarding Medical Use
3.5. Future Opportunity
4. MARKET LANDSCAPE: PSYCHEDELIC THERAPEUTICS
4.1. Chapter Overview
4.2. Psychedelic Therapeutics: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Psychedelic Substance
4.2.3. Analysis by Origin of Psychedelic Substance
4.2.4. Analysis by Target Therapeutic Area
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosing Frequency
4.3. Psychedelic Therapeutics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4. 3.3. Analysis by Location of Headquarters
4.4. Grid Analysis: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Celon Pharma
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Psychedelic Therapeutics Portfolio
5.2.3.1. Esketamine DPI
5.2.4. Recent Developments and Future Outlook
5.3. iX Biopharma
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Psychedelic Therapeutics Portfolio
5.3.3.1. Wafermine™
5.3.3.2. Unnamed (Ketamine)
5.3.4. Recent Developments and Future Outlook
5.4. MAPS Public Benefit
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Psychedelic Therapeutics Portfolio
5.4.3.1. Unnamed (MDMA)
5.4.3.2. Unnamed (Ibogaine Hydrochloride)
5.4.3.3. Unnamed (LSD)
5.4.3.4. Unnamed (Ayahuasca)
5.4.4. Recent Developments and Future Outlook
5.5. MindMed
5.5.1. Company Overview
5.5.2. Psychedelic Therapeutics Portfolio
5.5.2.1. Unnamed (LSD)
5.5.2.2. Unnamed (MDMA)
5.5.2.3. 18-MC
5.5.2.4. Unnamed (DMT)
5.5.2.5. Unnamed (LSD, MDMA)
5.5.3. Recent Developments and Future Outlook
5.6. Janssen Pharmaceuticals
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Psychedelic Therapeutics Portfolio
5.6.3.1. SPRAVATO®
5.6.4. Recent Developments and Future Outlook
5.7. Jazz Pharmaceutical
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Psychedelic Therapeutics Portfolio
5.7.3.1. XYREM®
5.7.3.2. JZP-258
5.7.3.3. JZP-324
5.7.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Psychedelic Therapeutics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase
6.3.3. Analysis by Trial Recruitment Status
6.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.5. Analysis by Study Design
6.3.6. Leading Trial Sponsors: Analysis by Number of Registered Trials
6.3.7. Leading Players: Analysis by Number of Registered Trials
6.3.8. Analysis by Trial Focus
6.3.9. Analysis by Target Therapeutic Area
6.3.10. Popular Psychedelic Substance: Analysis by Number of Registered Trials
6.3.11. Geographical Analysis by Number of Registered Trials
6.3.12. Geographical Analysis by Number of Patients Enrolled
7. CLINICAL TRIAL SITE ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Psychedelic Therapeutics: Clinical Trial Site Analysis
7.3.1. Analysis by Geographical Location
7.3.1.1. Clinical Trial Sites in North America
7.3.1.1.1. Analysis by Trial Phase
7.3.1.1.2. Analysis by Target Therapeutic Area
7.3.1.1.2. Analysis by Trial Phase and Target Therapeutic Area
7.3.1.2. Clinical Trial Sites in Europe
7.3.1.2.1. Analysis by Trial Phase
7.3.1.2.2. Analysis by Target Therapeutic Area
7.3.1.2.2. Analysis by Trial Phase and Target Therapeutic Area
7.3.1.3. Clinical Trial Sites in Asia Pacific
7.3.1.3.1. Analysis by Trial Phase
7.3.1.3.2. Analysis by Target Therapeutic Area
7.3.1.3.2. Analysis by Trial Phase and Target Therapeutic Area
8. KEY OPINION LEADER (KOL) ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.3.1. Analysis by Type of Organization (KOL Affiliation)
8.3.2. Geographical Distribution of KOLs
8.4. Prominent KOLs
8.5. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
8.6. Most Active KOLs
8.6.1. KOL Profile: A (Emory School of Medicine)
8.6.2. KOL Profile: B (Imperial College London)
8.6.3. KOL Profile: C (Rigshospitalet)
8.6.4. KOL Profile: D (Thriving Mind South Florida)
8.6.5. KOL Profile: E (University Health Network)
9. ACADEMIC GRANTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Psychedelic Therapeutics: Analysis of Academic Grants
9.3.1. Analysis by Year of Grant Award
9.3.2. Analysis by Amount Awarded
9.3.3. Analysis by Funding Institute Center
9.3.4. Analysis by Support Period
9.3.5. Analysis by Funding Institute Center and Support Period
9.3.6. Analysis by Type of Grant Application
9.3.7. Analysis by Purpose of Grant Award
9.3.8. Analysis by Activity Code
9.3.9. Analysis by Study Section Involved
9.3.10. Analysis by Recipient Organization
9.3.11. Geographical Distribution of Recipient Organizations
9.3.12. Word Cloud: Emerging Focus Areas
9.3.13. Popular Psychedelic Therapeutics: Analysis by Number of Grants
9.3.14. Popular Funding Institute Centers: Analysis by Number of Grants
9.3.15. Prominent Program Officers: Analysis by Number of Grants
9.3.16. Popular Recipient Organizations: Analysis by Number of Grants
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Psychedelic Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partnership and Type of Psychedelic Substance Involved
10.3.4. Analysis by Type of Partnership and Phase of Development of Involved Intervention
10.3.5. Analysis by Type of Partnership and Target Therapeutic Area Mentioned
10.3.6. Analysis by Type of Psychedelic Substance and Target Therapeutic Area
10.3.7. Analysis by Type of Partnership and Type of Partner
10.3.8. Analysis by Type of Psychedelic Substance Involved and Type of Partner
10.3.9. Most Active Players: Analysis by Number of Partnerships
10.3.10. Regional Analysis
10.3.10.1 Intercontinental and Intracontinental Agreements
11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Acquisition Models
11.3. Psychedelic Therapeutics: Mergers and Acquisitions
11.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
11.3.2. Analysis by Type of Agreement
11.3.3. Analysis by Type of Psychedelic Substance Involved
11.3.4. Analysis by Type of Agreement and Type of Psychedelic Substance Involved
11.3.5. Most Active Players: Analysis by Number of Acquisitions
11.3.6. Regional Analysis
11.3.6.1. Continent-Wise Distribution of Acquisitions
11.3.6.2. Country-Wise Distribution of Acquisitions
11.3.7. Analysis by Key Value Drivers
11.3.7.1. Analysis by Year of Acquisition and Key Value Drivers
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Psychedelic Therapeutics Market, 2020-2030
12.4. Global Psychedelic Therapeutics Market: Individual Product Sales Forecasts
12.4.1. Xyrem (Jazz Pharmaceutical)
12.4.1.1. Target Patient Population
12.4.1.2. Sales Forecast
12.4.2. Spravato (Janssen Pharmaceuticals)
12.4.2.1. Target Patient Population
12.4.2.2. Sales Forecast
12.4.3. JPZ-258 (Janssen Pharmaceuticals)
12.4.3.1. Target Patient Population
12.4.3.2. Sales Forecast
12.4.4. FT218 (Avadel Pharmaceuticals)
12.4.4.1. Target Patient Population
12.4.4.2. Sales Forecast
12.4.5. Unnamed MDMA (MAPS Public Benefit)
12.4.5.1. Target Patient Population
12.4.5.2. Sales Forecast
12.4.6. COMP360 (COMPASS Pathways)
12.4.6.1. Target Patient Population
12.4.6.2. Sales Forecast
12.4.7. Unnamed Psilocybin (The Emmes Company)
12.4.7.1. Target Patient Population
12.4.7.2. Sales Forecast
12.4.8. Esketamine DPI (Celon Pharma)
12.4.8.1. Target Patient Population
12.4.8.2. Sales Forecast
12.4.9. Wafermine (iX Biopharma)
12.4.9.1. Target Patient Population
12.4.9.2. Sales Forecast
12.5. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substance, 2020-2030
12.5.1. Global Psychedelic Therapeutics Market for Synthetic Substances, 2020-2030
12.5.2. Global Psychedelic Therapeutics Market for Natural Substances, 2020-2030
12.6. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, 2025-2030
12.6.1. Global Psychedelic Therapeutics Market for GHB, 2020-2030
12.6.2. Global Psychedelic Therapeutics Market for Ketamine, 2020-2030
12.6.3. Global Psychedelic Therapeutics Market for MDMA, 2021-2030
12.6.4. Global Psychedelic Therapeutics Market for Psilocybin, 2023-2030
12.7. Global Psychedelic Therapeutics Market: Distribution by Geography, 2020-2030
12.7.1. Global Psychedelic Therapeutics Market in North America, 2020-2030
12.7.2. Global Psychedelic Therapeutics Market in Europe, 2020-2030
12.7.3. Global Psychedelic Therapeutics Market in Asia Pacific, 2022-2030
12.8. Global Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030
12.8.1. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, 2020-2030
12.8.2. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, 2020-2030
12.8.3. Global Psychedelic Therapeutics Market for Trauma, 2021-2030
12.8.4. Global Psychedelic Therapeutics Market for Pain Disorders, 2026-2030
12.9. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, 2020-2030
12.9.1. Global Psychedelic Therapeutics Market for Oral Therapies, 2020-2030
12.9.2. Global Psychedelic Therapeutics Market for Intranasal Therapies, 2020-2030
12.9.3. Global Psychedelic Therapeutics Market for Sublingual Therapies, 2026-2030
13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2 CaaMTech
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Andrew Chadeayne, Founder & Chief Executive Officer
14.3. iX Biopharma
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer
14.4 Orthogonal Thinkers
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Tracy Cheung, Alexander Speiser, Chief Operating Officer
14.5 COMPASS Pathways
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Tracy Cheung, Chief Communications Officer
14.7 Yale University
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Benjamin Kelmendi, Assistant Professor of Psychiatry
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415